comprehensive -WSS

comprehensive

author：hotspot 2025-09-27 16:23:19 - browse：5611

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Medicare Advantage enrollment grows 7.1% to 33.4 million people

focus

WSS

Hospitals are piloting generative AI tools as regulators play catch

Congress may force more Covid

Illumina board agrees to spin off Grail, as divestment plans proceed

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Reporting on presidential health from Reagan to Trump and Biden

focus

comprehensive

focus

Duchenne breakthrough therapy leaves behind pioneering families

Reporting on presidential health from Reagan to Trump and Biden

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

https://cbu01.alicdn.com/img/ibank/2017/914/731/4162137419_1509971307.220x220xz.jpg

At least 13 dead in Texas as scorching temps continue

ASCO Takeaways: Winners, snoozers, and the art of cancer care

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Obamacare plans could cover weight loss drugs

Trump demands the U.S. pay no more for drugs than other countries … again

Reporting on presidential health from Reagan to Trump and Biden

hotspot

Stopping antidepressants leads to symptoms for 1 in 6 patients

As AI regulations shape up, health tech startups beg for clarity

Flagship Pioneering startup Sonata Therapeutics lays off 21

FDA warns medical device makers about rise in fabricated data

CMS got Medicare Advantage quality rating wrong, judge rules

Abridge raises $150m as clinical notes automation market heats up

focus

focus

entertainment

knowledge